BM R15
Alternative Names: BM-R15Latest Information Update: 02 Sep 2024
Price :
$50 *
At a glance
- Originator Shenzhen Beimei Pharmaceutical
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acne vulgaris
Most Recent Events
- 05 Aug 2024 Preclinical trials in Acne vulgaris in China (unspecified route), prior to August 2024 (Shenzhen Beimei Pharmaceutical pipeline, August 2024)